Identification

Name
Enoxacin
Accession Number
DB00467  (APRD00947)
Type
Small Molecule
Groups
Approved, Investigational
Description

A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. [PubChem]

Structure
Thumb
Synonyms
  • 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
  • 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
  • Enoxacin
  • Enoxacina
  • Énoxacine
  • Enoxacino
  • Enoxacinum
External IDs
AT 2266 / AT-2266 / CI 919 / CI-919 / PD 107779 / PD-107779
International/Other Brands
Almitil / Bactidan / Comprecin / Enoksetin / Enoxen / Enoxin / Enoxor (Pierre Fabre) / Enoxor / Enroxil / Flumark / Gyramid / Penetrex / Vinone
Categories
UNII
325OGW249P
CAS number
74011-58-8
Weight
Average: 320.3189
Monoisotopic: 320.128468635
Chemical Formula
C15H17FN4O3
InChI Key
IDYZIJYBMGIQMJ-UHFFFAOYSA-N
InChI
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
IUPAC Name
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1

Pharmacology

Indication

For the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae, (2) uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus, and (3) complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae.

Structured Indications
Not Available
Pharmacodynamics

Enoxacin is a quinolone/fluoroquinolone antibiotic. Enoxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Enoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Enoxacin may be active against pathogens resistant to drugs that act by different mechanisms.

Mechanism of action

Enoxacin exerts its bactericidal action via the inhibition of the essential bacterial enzyme DNA gyrase (DNA Topoisomerase II).

TargetActionsOrganism
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
NDNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Rapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%.

Volume of distribution
Not Available
Protein binding

Enoxacin is approximately 40% bound to plasma proteins in healthy subjects and is approximately 14% bound to plasma proteins in patients with impaired renal function.

Metabolism

Hepatic. Some isozymes of the cytochrome P-450 hepatic microsomal enzyme system are inhibited by enoxacin. After a single dose, greater than 40% was recovered in urine by 48 hours as unchanged drug.

Route of elimination
Not Available
Half life

Plasma half-life is 3 to 6 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Enoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Enoxacin.Experimental, Illicit
AcarboseEnoxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Enoxacin.Approved
AcenocoumarolEnoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Enoxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Enoxacin.Approved
AlbiglutideEnoxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Enoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Enoxacin.Experimental, Investigational
AlgeldrateAlgeldrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmagateAlmagate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Enoxacin.Experimental
AlogliptinEnoxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Enoxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Enoxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Enoxacin.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Enoxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Enoxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Enoxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Enoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Enoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Enoxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Enoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Enoxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Enoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Enoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enoxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Enoxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Enoxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Enoxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Enoxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Enoxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Enoxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Enoxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Enoxacin.Approved
BromocriptineEnoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Enoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Enoxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Enoxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Enoxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enoxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinEnoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Enoxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Enoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
ChlorpropamideEnoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Enoxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Enoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Enoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Enoxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Enoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Enoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Enoxacin.Approved
ClorindioneEnoxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Enoxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Enoxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Enoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Enoxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Enoxacin.Experimental
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Enoxacin.Investigational
DapagliflozinEnoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Enoxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Enoxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Enoxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Enoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Enoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Enoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Enoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
DicoumarolEnoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Enoxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Enoxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Enoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Enoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Enoxacin.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Enoxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Enoxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enoxacin.Approved
DiphenadioneEnoxacin may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideEnoxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Enoxacin.Approved
DulaglutideEnoxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Enoxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Enoxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Enoxacin.Investigational
EmpagliflozinEnoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Enoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Enoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Enoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Enoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Enoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Enoxacin.Experimental
Ethyl biscoumacetateEnoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
ExenatideEnoxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Enoxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Enoxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Enoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Enoxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Enoxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Enoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Enoxacin can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Enoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Enoxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Enoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Enoxacin.Approved
FluindioneEnoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Enoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Enoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Enoxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Enoxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Enoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Enoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Enoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Enoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Enoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Enoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Enoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Enoxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Enoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Enoxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Enoxacin.Experimental
GliclazideEnoxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEnoxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEnoxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideEnoxacin may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Enoxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Enoxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Enoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Enoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Enoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Enoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Enoxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Enoxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Enoxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Enoxacin.Withdrawn
Insulin AspartEnoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEnoxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEnoxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEnoxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEnoxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEnoxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Enoxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Enoxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Enoxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Enoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Enoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Enoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Enoxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Enoxacin.Experimental
Lanthanum carbonateThe serum concentration of Enoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
LiraglutideEnoxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Enoxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Enoxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Enoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Enoxacin.Investigational
MecaserminEnoxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Enoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Enoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Enoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Enoxacin.Investigational, Withdrawn
MetforminEnoxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enoxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Enoxacin.Experimental
MifepristoneEnoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolEnoxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Enoxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Enoxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Enoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Enoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
NateglinideEnoxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Enoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Enoxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Enoxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Enoxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Enoxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Enoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Enoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Enoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Enoxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Enoxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Enoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enoxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Enoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Enoxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Enoxacin.Investigational
PentamidineEnoxacin may increase the hypoglycemic activities of Pentamidine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Enoxacin.Experimental
PhenindioneEnoxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEnoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enoxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PioglitazoneEnoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Enoxacin.Experimental
PramlintideEnoxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Enoxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Enoxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Enoxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Enoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Enoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Enoxacin.Experimental, Investigational
ProbenecidThe serum concentration of Enoxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Enoxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Enoxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Enoxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Enoxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Enoxacin.Investigational
QuinaprilThe serum concentration of Enoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineEnoxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideEnoxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Enoxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Enoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Enoxacin.Investigational, Withdrawn
RosiglitazoneEnoxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Enoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Enoxacin.Approved
SaxagliptinEnoxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Enoxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Enoxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Enoxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinEnoxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Enoxacin.Investigational
Strontium ranelateThe serum concentration of Enoxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Enoxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineEnoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleEnoxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Enoxacin.Approved
SulfisoxazoleEnoxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Enoxacin.Approved
SunitinibEnoxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Enoxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Enoxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Enoxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Enoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Enoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Enoxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Enoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Enoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Enoxacin.Investigational
TioclomarolEnoxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Enoxacin.Approved
TolazamideEnoxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideEnoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Enoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Enoxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Enoxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Enoxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Enoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Enoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Enoxacin.Approved, Investigational
WarfarinEnoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Enoxacin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
US4359578
General References
Not Available
External Links
Human Metabolome Database
HMDB14610
KEGG Drug
D00310
KEGG Compound
C06979
PubChem Compound
3229
PubChem Substance
46507505
ChemSpider
3116
BindingDB
50296358
ChEBI
157175
ChEMBL
CHEMBL826
Therapeutic Targets Database
DAP001000
PharmGKB
PA449462
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Enoxacin
ATC Codes
J01MA04 — Enoxacin
MSDS
Download (44.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220-224 °CPhysProp
water solubility3.43 g/LNot Available
logP-0.20SANGSTER (1994) (ION-CORRECT)
Predicted Properties
PropertyValueSource
Water Solubility1.09 mg/mLALOGPS
logP-0.97ALOGPS
logP-0.98ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)5.5ChemAxon
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area85.77 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity83.95 m3·mol-1ChemAxon
Polarizability31.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8683
P-glycoprotein inhibitor INon-inhibitor0.8978
P-glycoprotein inhibitor IINon-inhibitor0.8606
Renal organic cation transporterNon-inhibitor0.7736
CYP450 2C9 substrateNon-substrate0.8078
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8862
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5351
Ames testAMES toxic0.9124
CarcinogenicityNon-carcinogens0.802
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6527
hERG inhibition (predictor II)Non-inhibitor0.5448
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0009000000-c343d2455564f9c283ab
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0039000000-c8fb064ca8dcd22fd051
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0069000000-6f1cc68c72c995af1700
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-0195000000-f089fb10889524908bb9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0391000000-342a8fc923e2f74b2c2f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0970000000-ad4c54479d1e64d34d71
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0pc0-2691000000-70495182f5d53b3e2f3e

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Naphthyridines
Direct Parent
Naphthyridine carboxylic acids and derivatives
Alternative Parents
Pyridinylpiperazines / N-arylpiperazines / Fluoroquinolones / Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Aryl fluorides / Imidolactams / Vinylogous amides / Heteroaromatic compounds
show 10 more
Substituents
Naphthyridine carboxylic acid / Fluoroquinolone / N-arylpiperazine / Pyridinylpiperazine / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine / Aminopyridine / Aryl fluoride / Aryl halide
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, monocarboxylic acid, amino acid, 1,8-naphthyridine derivative, quinolone antibiotic, fluoroquinolone antibiotic (CHEBI:157175)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S: Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 1993 Apr;37(4):839-45. [PubMed:8388200]
  4. Weisser J, Wiedemann B: Elimination of plasmids by enoxacin and ofloxacin at near inhibitory concentrations. J Antimicrob Chemother. 1986 Nov;18(5):575-83. [PubMed:3542924]
  5. Courtright JB, Turowski DA, Sonstein SA: Alteration of bacterial DNA structure, gene expression, and plasmid encoded antibiotic resistance following exposure to enoxacin. J Antimicrob Chemother. 1988 Feb;21 Suppl B:1-18. [PubMed:2834313]
  6. Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. [PubMed:3282749]
  7. Castora FJ, Vissering FF, Simpson MV: The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. Biochim Biophys Acta. 1983 Sep 9;740(4):417-27. [PubMed:6309236]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. [PubMed:3282749]
  4. Takahashi H, Hayakawa I, Akimoto T: [The history of the development and changes of quinolone antibacterial agents]. Yakushigaku Zasshi. 2003;38(2):161-79. [PubMed:15143768]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Maki T, Hirono I, Kondo H, Aoki T: Drug resistance mechanism of the fish-pathogenic bacterium Lactococcus garvieae. J Fish Dis. 2008 Jun;31(6):461-8. doi: 10.1111/j.1365-2761.2008.00927.x. [PubMed:18471102]
  3. Snyder RD, Cooper CS: Photogenotoxicity of fluoroquinolones in Chinese hamster V79 cells: dependency on active topoisomerase II. Photochem Photobiol. 1999 Mar;69(3):288-93. [PubMed:10089819]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:38